Algert Global LLC Reduces Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Algert Global LLC lowered its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 32.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 124,937 shares of the company's stock after selling 59,948 shares during the quarter. Algert Global LLC owned approximately 0.15% of Progyny worth $2,155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PDT Partners LLC purchased a new stake in shares of Progyny during the 4th quarter worth $3,461,000. Voya Investment Management LLC boosted its position in shares of Progyny by 1.4% during the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after acquiring an additional 701 shares in the last quarter. Quantessence Capital LLC acquired a new position in shares of Progyny during the 4th quarter worth about $243,000. Hsbc Holdings PLC increased its holdings in shares of Progyny by 20.1% in the 4th quarter. Hsbc Holdings PLC now owns 35,095 shares of the company's stock valued at $603,000 after acquiring an additional 5,877 shares during the last quarter. Finally, Stifel Financial Corp raised its position in shares of Progyny by 48.5% during the 4th quarter. Stifel Financial Corp now owns 71,736 shares of the company's stock worth $1,237,000 after acquiring an additional 23,425 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $2.17 during trading on Friday, reaching $21.20. The company had a trading volume of 3,566,405 shares, compared to its average volume of 1,722,248. The stock's fifty day moving average price is $21.95 and its 200 day moving average price is $19.56. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $30.42. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The business had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on PGNY. JPMorgan Chase & Co. increased their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research report on Monday, March 31st. Canaccord Genuity Group boosted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. Finally, Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Progyny presently has an average rating of "Hold" and a consensus target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.